Effectivity of Long Antigen Exposition Dendritic Cell Therapy (LANEXDC®) in the Palliative Treatment of Pancreatic Cancer
October 2013, Current Medicinal Chemistry 20(38) (DOI:10.2174/09298673113206660290)
June 2015, Gastroenterology Research and Practice 2015:1-7 (DOI:10.1155/2015/231243)
Feasibility of dc vaccine combined with low dose endoxan and high dose il-2 treatment associated with taurolidine for advanced, multi-resistant melanoma patients.
November 2015, J Immunother Cancer. 2015; 3(Suppl 2): P209 (DOI: 10.1186/2051-1426-3-S2-P209)
Near complete remission of pulmonary metastases in triple negative breast cancer (TNBC) using low-dose immune checkpoint (IC) inhibitors with high dose (HD) interleukin-2 (IL-2) and fever range hyperthermia.
May 2016, Journal of Clinical Oncology 34(15_suppl):e23111-e23111 (DOI:10.1200/JCO.2016.34.15_suppl.e23111)
March 2017, Journal for ImmunoTherapy of Cancer 5(S1) (DOI:10.1186/s40425-017-0219-4)
Complete clinical remission of stage IV breast cancer with liver, lung, bone and lymph node metastasis combining low-dose checkpoint inhibitors with interleukin-2 (IL-2) and fever range hyperthermia and metronomic low-dose chemotherapy
March 2018, European Journal of Cancer 92(1):S13 (DOI:10.1016/j.ejca.2018.01.034)
Complete Clinical Remission of Stage IV Triple-Negative Breast Cancer Lung Metastasis Administering Low-Dose Immune Checkpoint Blockade in Combination With Hyperthermia and Interleukin-2
September 2018, Integrative Cancer Therapies 17(4):153473541879486 (DOI:10.1177/1534735418794867)
Complete response of stage IV pancreatic cancer combining low-dose checkpoint inhibitors with interleukin-2 (IL-2) and fever range hyperthermia
March 2019, European Journal of Cancer 110(1): S22 (DOI:10.1016/j.ejca.2019.01.073) April 2019, ITOC 6 Conference, poster presentation
October 2019, Scandinavian Journal of Immunology 90(191) (DOI:10.1111/sji.12821)